Skip to content
DataLookout
Menu

NCT07929298

A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage Change in Body Weight
Timeframe: Baseline, week 24

Secondary (15)

Percentage of Participants with ≥5% of Body Weight Loss
Percentage of Participants with ≥10% of Body Weight Loss
Percentage of Participants with ≥15% of Body Weight Loss
Absolute Change in Body Weight
Change in Body Mass Index (BMI)
Show 10 moreShow less
Change in blood pressure
Change in other body measurements
Change in lipid profile
Change in fasting blood glucose (FBG)
Change in HbA1c
Change in fasting insulin
Change in blood uric acid
Change in liver enzymes
Adverse events
Plasma Concentration of Ecnoglutide

Arms and interventions

oral ecnoglutide dose 1Experimental

once daily from week1 to week 8, then once weekly from week 9 to week 24

oral ecnoglutide dose 2Experimental

once daily from week1 to week 8, then once weekly from week 9 to week 24

oral ecnoglutide dose 3Experimental

once daily from week1 to week 12, then once weekly from week 13 to week 24

PlaceboPlacebo comparator

once daily from week1 to week 8 or week 12, then once weekly from week 9 or week 13 to week 24

oral ecnoglutide dose 4Experimental

once daily from week1 to week 12, then once weekly from week 13 to week 24

Drugs: ecnoglutide tablet, placebo with matching dosage

Sites

1 site in 1 country

  • The First Affiliated Hospital of Henan University of Science & TechnologyLuoyang, Henan, China